Stock Events

Nuformix 

GBX0.27
4
-GBX0-0.95% Tuesday 14:26

Statistics

Day High
0.3
Day Low
0.27
52W High
0.44
52W Low
0.2
Volume
277,900
Avg. Volume
2,513,017
Mkt Cap
2.32M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26JulExpected
Q2 2021
Q2 2022
Q4 2022
Q2 2023
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NFX.LSE. It's not an investment recommendation.

About

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. Its lead programs include NXP001, which is in Phase 1-ready stage for oncology supportive care; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. The company is also developing NXP004, which is in the research Phase for treating oncology. It also has an option agreement with Oxilio Ltd. for developing and exploiting NXP001 for the treatment of cancer. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Show more...
CEO
Dr. Anne Brindley
Employees
5
Country
GB
ISIN
GB00BYW79Y38
WKN
000A141LG

Listings